Point72 Asset Management L.P. Sells 1,270,000 Shares of DBV Technologies S.A. (NASDAQ:DBVT)

Point72 Asset Management L.P. decreased its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) by 81.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 286,250 shares of the company's stock after selling 1,270,000 shares during the quarter. Point72 Asset Management L.P. owned about 1.39% of DBV Technologies worth $885,000 at the end of the most recent quarter.

Separately, Boxer Capital Management LLC bought a new position in shares of DBV Technologies during the fourth quarter worth $154,000. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

DBVT has been the subject of a number of research reports. HC Wainwright upped their target price on shares of DBV Technologies from $7.00 to $16.00 and gave the stock a "buy" rating in a research report on Monday, May 5th. JMP Securities upped their target price on shares of DBV Technologies from $15.00 to $21.00 and gave the stock a "market outperform" rating in a research report on Tuesday. Finally, Wall Street Zen upgraded shares of DBV Technologies from a "sell" rating to a "hold" rating in a research report on Friday, May 9th.

DBV Technologies Stock Up 11.7%

DBV Technologies stock traded up $0.99 during mid-day trading on Tuesday, reaching $9.40. 114,766 shares of the company's stock traded hands, compared to its average volume of 190,400. The company has a market cap of $257.33 million, a price-to-earnings ratio of -2.09 and a beta of -0.66. The stock has a 50 day moving average of $8.10 and a two-hundred day moving average of $5.36. DBV Technologies S.A. has a 12-month low of $2.20 and a 12-month high of $12.78.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its earnings results on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. The firm had revenue of $0.51 million during the quarter. As a group, sell-side analysts forecast that DBV Technologies S.A. will post -7.05 earnings per share for the current year.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.